{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:18:13Z","timestamp":1768681093312,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005945","name":"Hirosaki University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K16570"],"award-info":[{"award-number":["20K16570"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.neulet.2023.137248","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T10:26:22Z","timestamp":1681381582000},"page":"137248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"806","author":[{"given":"Yoshiki","family":"Murakami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1065-664X","authenticated-orcid":false,"given":"Haruo","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iku","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Kon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neulet.2023.137248_b0005","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neulet.2023.137248_b0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2011.212","article-title":"Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa","volume":"37","author":"Smith","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neulet.2023.137248_b0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00702-021-02306-2","article-title":"Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials","volume":"128","author":"Danysz","year":"2021","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.neulet.2023.137248_b0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-8993(03)02531-9","article-title":"Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats","volume":"972","author":"Arai","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neulet.2023.137248_b0025","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","article-title":"Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease","volume":"15","author":"Luginger","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2023.137248_b0030","doi-asserted-by":"crossref","first-page":"e15298","DOI":"10.1371\/journal.pone.0015298","article-title":"Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial","volume":"5","author":"Sawada","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2023.137248_b0035","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.26159","article-title":"Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)","volume":"30","author":"Pahwa","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2023.137248_b0040","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","article-title":"ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neulet.2023.137248_b0045","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)","volume":"32","author":"Oertel","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2023.137248_b0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mdc3.12595","article-title":"Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102","volume":"5","author":"Isaacson","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.neulet.2023.137248_b0055","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson's disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neulet.2023.137248_b0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41531-022-00291-1","article-title":"Amantadine delayed release\/extended release capsules significantly reduce OFF time in Parkinson's disease","volume":"8","author":"Hauser","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.neulet.2023.137248_b0065","doi-asserted-by":"crossref","unstructured":"O. Rascol, L. Tonges, T. deVries, M. Jaros, A. Quartel, D. Jacobs, I. Allay-Lid, and A.-L.I.s. groups, Immediate-release\/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism Relat. Disord. 96 (2022) 65-73.","DOI":"10.1016\/j.parkreldis.2022.01.022"},{"key":"10.1016\/j.neulet.2023.137248_b0070","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neulet.2023.137248_b0075","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","article-title":"Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study","volume":"56","author":"Metman","year":"1999","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neulet.2023.137248_b0080","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/mds.23034","article-title":"Long-term antidyskinetic efficacy of amantadine in Parkinson's disease","volume":"25","author":"Wolf","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2023.137248_b0085","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","article-title":"Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial","volume":"82","author":"Ory-Magne","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2023.137248_b0090","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00002826-198712000-00003","article-title":"Amantadine and motor fluctuations in chronic Parkinson's disease","volume":"10","author":"Shannon","year":"1987","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neulet.2023.137248_b0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s007020170086","article-title":"Co-administration of memantine and amantadine with sub\/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice","volume":"108","author":"Fredriksson","year":"2001","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.neulet.2023.137248_b0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neulet.2023.137248_b0105","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/mds.23867","article-title":"Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease","volume":"26","author":"Kobylecki","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2023.137248_b0110","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1471-4159.2011.07376.x","article-title":"Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels","volume":"118","author":"Bido","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2023.137248_b0115","doi-asserted-by":"crossref","unstructured":"M. Bortolanza, K.D. Bariotto-Dos-Santos, M. Dos-Santos-Pereira, C.A. da-Silva, and E. Del-Bel, Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease. Neurotox. Res. 30 (2016) 88-100.","DOI":"10.1007\/s12640-016-9618-4"},{"key":"10.1016\/j.neulet.2023.137248_b0120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","article-title":"Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats","volume":"10","author":"Tanaka","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.neulet.2023.137248_b0125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2014.01.042","article-title":"Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease","volume":"265","author":"Tronci","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neulet.2023.137248_b0130","first-page":"8626783","article-title":"Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease","volume":"2018","author":"Nishijima","year":"2018","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.neulet.2023.137248_b0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/neup.12009","article-title":"Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia","volume":"33","author":"Nishijima","year":"2013","journal-title":"Neuropathology"},{"key":"10.1016\/j.neulet.2023.137248_b0140","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neulet.2023.137248_b0145","doi-asserted-by":"crossref","unstructured":"M.A. Cenci, and M. Lundblad, Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci Chapter 9 (2007) Unit 9 25.","DOI":"10.1002\/0471142301.ns0925s41"},{"key":"10.1016\/j.neulet.2023.137248_b0150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/exnr.1998.6819","article-title":"Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"151","author":"Henry","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neulet.2023.137248_b0155","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/mds.27337","article-title":"Animal models of l-dopa-induced dyskinesia in Parkinson's disease","volume":"33","author":"Cenci","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2023.137248_b0160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.mcn.2017.01.004","article-title":"The role of drebrin in dendritic spines","volume":"84","author":"Koganezawa","year":"2017","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neulet.2023.137248_b0165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cne.20449","article-title":"Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses","volume":"483","author":"Aoki","year":"2005","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neulet.2023.137248_b0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbr.2003.10.009","article-title":"Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias","volume":"152","author":"Delfino","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neulet.2023.137248_b0175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neulet.2023.137248_b0180","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2023.137248_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173393","article-title":"The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats","volume":"217","author":"Cohen","year":"2022","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.neulet.2023.137248_b0190","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mds.22917","article-title":"NMDA antagonist memantine improves levodopa-induced dyskinesias and \u201con-off\u201d phenomena in Parkinson's disease","volume":"25","author":"Varanese","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2023.137248_b0195","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jgs.12058","article-title":"Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia","volume":"61","author":"Vidal","year":"2013","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.neulet.2023.137248_b0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ane.12468","article-title":"Memantine and reduced time with dyskinesia in Parkinson's Disease","volume":"133","author":"Wictorin","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neulet.2023.137248_b0205","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3389\/fneur.2019.01258","article-title":"Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism","volume":"10","author":"Ogawa","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neulet.2023.137248_b0210","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/mds.25826","article-title":"Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model","volume":"29","author":"Nishijima","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2023.137248_b0215","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/mds.27172","article-title":"Levodopa treatment and dendritic spine pathology","volume":"33","author":"Nishijima","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2023.137248_b0220","doi-asserted-by":"crossref","unstructured":"H. Nishijima, T. Nakamura, and M. Tomiyama, Morphological and Functional Changes of Striatal Neurons with L-dopa-induced Dyskinesia. Neurol. Clin. Neurosci. In Press (2021).","DOI":"10.1111\/ncn3.12562"},{"key":"10.1016\/j.neulet.2023.137248_b0225","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrn2699","article-title":"Experience-dependent structural synaptic plasticity in the mammalian brain","volume":"10","author":"Holtmaat","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neulet.2023.137248_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109130","article-title":"Shootin1a-mediated actin-adhesion coupling generates force to trigger structural plasticity of dendritic spines","volume":"35","author":"Kastian","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.neulet.2023.137248_b0235","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.104.066191","article-title":"Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"310","author":"Hill","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2023.137248_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104979","article-title":"GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming","volume":"143","author":"Nishijima","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neulet.2023.137248_b0245","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archneur.62.6.905","article-title":"Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study","volume":"62","author":"Stocchi","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neulet.2023.137248_b0250","unstructured":"A. Antonini, W. Poewe, K.R. Chaudhuri, R. Jech, B. Pickut, Z. Pirtosek, J. Szasz, F. Valldeoriola, C. Winkler, L. Bergmann, A. Yegin, K. Onuk, D. Barch, P. Odin, and G.s. co-investigators, Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism Relat. Disord. 45 (2017) 13-20."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394023002070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394023002070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:01:55Z","timestamp":1736348515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394023002070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":50,"alternative-id":["S0304394023002070"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2023.137248","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2023.137248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"137248"}}